Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07044908 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer

StatusRecruiting
PhasePhase 1/2
Started2025-07-30
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 12, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2025-08-11
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-07→confirmed 2025-07-30
Study sitesdetails revised at 27 of 27 sites
2025-06-23
Original filing
This is a multicenter, open Phase Ib/II clinical study evaluating the safety and efficacy of TQB2922 in combination with TAS-102±bevacizumab in subjects with RAS/BRAF wild-type unresectable locally advanced or metastatic colorectal cancer that has failed treatment with oxaliplatin, fluorouracil-based and irinotecan.
Trial Details
NCT Number NCT07044908
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions RAS/BRAF Wild Type Colorectal Cancer
Enrollment 72 participants
Start Date 2025-07-30
Primary Completion 2026-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-08-12